Publication Name	World Journal of Clinical Cases
Manuscript ID	100262
Country	China

Received	2024-08-11 16:47
Peer-Review Started	2024-08-11 16:47
To Make the First Decision
Return for Revision	2024-12-12 07:45
Revised	2024-12-22 02:57
Second Decision	2024-12-30 02:43
Accepted by Journal Editor-in-Chief
Accepted by Executive Editor-in-Chief	2024-12-30 08:50
Articles in Press	2024-12-30 08:50
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript	2025-01-13 01:18
Publish the Manuscript Online	2025-01-15 03:58

ISSN	2307-8960 (online)
Open Access	This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Copyright	© The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions	For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher	Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website	http://www.wjgnet.com

Category	Medicine, Research & Experimental
Manuscript Type	Letter to the Editor
Article Title	Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management
Manuscript Source	Invited Manuscript
All Author List	Xiao-Peng Fu
ORCID	Author(s) ORCID Number Xiao-Peng Fu http://orcid.org/0009-0003-6548-4368
Funding Agency and Grant Number
Corresponding Author	Xiao-Peng Fu, College of Traditional Chinese Medicine, Fujian University of Traditional Chinese Medicine, No. 1 Qiuyang Road, Fuzhou 350122, Fujian Province, China. 1220105011@fjtcm.edu.cn
Key Words	Sodium-glucose cotransporter 2 inhibitors; Hyperuricemia; Gout; Uric acid reduction; Chronic heart failure
Core Tip	This article explores the dual benefits of sodium-glucose cotransporter 2 (SGLT2) inhibitors in managing hyperuricemia and gout, particularly in patients with type 2 diabetes and cardiovascular complications. By highlighting the ability of SGLT2 inhibitors to lower uric acid levels and reduce the risk of gout flare-ups, this article provides insights into their potential as a comprehensive treatment option. The review also emphasizes the importance of understanding the underlying mechanisms, offering a new perspective on optimizing the clinical application of SGLT2 inhibitors in high-risk patients.
Publish Date	2025-01-15 03:58
Citation	<p>Fu XP. Dual benefits of sodium-glucose cotransporter 2 inhibitors in metabolic diseases: Diabetes control and gout management. <i>World J Clin Cases</i> 2025; 13(14): 100262</p>
URL	https://www.wjgnet.com/2307-8960/full/v13/i14/100262.htm
DOI	https://dx.doi.org/10.12998/wjcc.v13.i14.100262

Full Article (PDF)	WJCC-13-100262-with-cover.pdf
Manuscript File	100262_Auto_Edited_122013.docx
Answering Reviewers	100262-answering-reviewers.pdf
Audio Core Tip	100262-audio.aac
Conflict-of-Interest Disclosure Form	100262-conflict-of-interest-statement.pdf
Copyright License Agreement	100262-copyright-assignment.pdf
Non-Native Speakers of English Editing Certificate	100262-non-native-speakers.docx
Peer-review Report	100262-peer-reviews.pdf
Scientific Misconduct Check	100262-scientific-misconduct-check.png
Scientific Editor Work List	100262-scientific-editor-work-list.pdf
CrossCheck Report	100262-crosscheck-report.pdf